1767 related articles for article (PubMed ID: 24915582)
1. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
2. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
3. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of femoropopliteal artery drug-eluting balloons and drug-eluting stents (FOREST trial): Study protocol for a randomized controlled trial.
Jongsma H; van Mierlo-van den Broek P; Imani F; van den Heuvel D; de Vries JPM; Fioole B
J Vasc Surg; 2017 Oct; 66(4):1293-1298. PubMed ID: 28826727
[TBL] [Abstract][Full Text] [Related]
5. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
Schmidt A; Piorkowski M; Görner H; Steiner S; Bausback Y; Scheinert S; Banning-Eichenseer U; Staab H; Branzan D; Varcoe RL; Scheinert D
JACC Cardiovasc Interv; 2016 Apr; 9(7):715-24. PubMed ID: 27056311
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Herten M; Torsello GB; Schönefeld E; Imm B; Osada N; Stahlhoff S
J Vasc Surg; 2015 Feb; 61(2):394-9. PubMed ID: 25307133
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
[TBL] [Abstract][Full Text] [Related]
8. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2013 Mar; 6(3):282-9. PubMed ID: 23517840
[TBL] [Abstract][Full Text] [Related]
9. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
[TBL] [Abstract][Full Text] [Related]
11. Midterm Patency After Femoropopliteal Interventions: A Comparison of Standard and Interwoven Nitinol Stents and Drug-Coated Balloons in a Single-Center, Propensity Score-Matched Analysis.
Steiner S; Schmidt A; Bausback Y; Piorkowski M; Werner M; Yahiaoui-Doktor M; Banning-Eichenseer U; Scheinert D
J Endovasc Ther; 2016 Apr; 23(2):347-55. PubMed ID: 26848131
[TBL] [Abstract][Full Text] [Related]
12. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
[No Abstract] [Full Text] [Related]
13. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
14. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
[TBL] [Abstract][Full Text] [Related]
15. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
[TBL] [Abstract][Full Text] [Related]
16. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
17. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
[TBL] [Abstract][Full Text] [Related]
18. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
19. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
20. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
